Characteristics of the 665 patients with RA (aged 40–80 years) included in the study.
| Characteristics | Values |
|---|---|
| Demographic | |
| Age at inclusion, yrs, mean (SD) | 58.3 (10.0) |
| Female, n (%) | 467 (69) |
| Cardiovascular risk factors | |
| Diabetes, n (%) | 43 (6.4) |
| Current smoking, n (%) | 188 (28) |
| Systolic BP, mmHg, mean (SD) | 144 (20) |
| Diastolic BP, mmHg, mean (SD) | 83 (10) |
| Antihypertensive treatment, n (%) | 163 (20) |
| Antihypertensive treatment and/or BP > 140/90, n (%) | 356 (53) |
| Cholesterol, mmol/l, mean (SD) | 5.69 (1.11) |
| HDL cholesterol, mmol/l, mean (SD) | 1.52 (0.49) |
| Triglycerides, mmol/l, mean (SD) | 1.48 (0.71) |
| Statin treatment, n (%) | 45 (6.7) |
| Statin treatment and/or hyperlipidemia, n (%) | 495 (73) |
| BMI, kg/m2, mean (SD) | 26.8 (4.3) |
| RA variables | |
| ESR, mm/h, median (IQR) | 24 (12–40) |
| CRP, mg/l, median (IQR) | 10 (7–26) |
| CDAI, median (IQR) | 21 (13–30) |
| CDAI > 10, n (%) | 569 (85.6) |
| Tender joint count, n, median (IQR) | 5 (2–9) |
| Swollen joint count, n, median (IQR) | 6 (3–10) |
| DAS28, median (IQR) | 4.7 (3.7–5.6) |
| HAQ median (IQR) | 0.75 (0.38–1.25) |
| HAQ > 0.5, n (%) | 456 (68.6) |
| Patient global VAS, mm, median (IQR) | 45 (23–64) |
| Positive anti-CCP, n (%) | 423/611 (69) |
| Corticosteroids, n (%) | 342 (51.4) |
RA: rheumatoid arthritis; BP: blood pressure; HDL: high-density lipoproteins; BMI: body mass index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; CDAI: Clinical Disease Activity Index; DAS28: 28-joint count Disease Activity Score; HAQ: Health Assessment Questionnaire; VAS: visual analog scale; anti-CCP: anticyclic citrullinated peptide antibodies; IQR: interquartile range.